Use of activated recombinant factor VII (NovoSeven) during neurosurgery

Journal of Neurosurgical Anesthesiology

Volumn 15, Issue 4, 2003, Pages 330-332

  Karadimov, Dimitar ^a   Binev, Krassimir ^a   Nachkov, Yanko ^a   Platikanov, Viliyan ^b  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^b University Hospital   (Bulgaria)

Author keywords

Intracranial bleeding; Recombinant factor VIIa

Indexed keywords

ELECTROLYTE; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; BLOOD TRANSFUSION; BODY WEIGHT; BRAIN HEMORRHAGE; BRAIN TUMOR; CASE REPORT; DRUG EFFICACY; FEMALE; HEMATOCRIT; HEMOSTASIS; HUMAN; MALE; MENINGIOMA; NEUROSURGERY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; TERATOMA;

ADULT; BRAIN NEOPLASMS; FACTOR VII; FEMALE; HEMORRHAGE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MALE; MENINGIOMA; NEUROSURGICAL PROCEDURES; TERATOMA;

EID: 0141641001     PISSN: 08984921     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008506-200310000-00008     Document Type: Article

References (5)

1. Jurlander B, Thim L, Klausen NK, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin Thromb Hemost. 2001;27:373-384
2. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:543-547.
3. Gerlach R, Marquardt G, Wissing H, et al. Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis: case report. J Neurosurg. 2002;96:946-948.
4. The Novo Seven package insert. Princeton, NJ. Novo Nordisk Pharmaceuticals Inc., 1993.
5. Aldouri M. The use of recombinant Factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb. 2002;32(suppl 1):41-46.